Skip to main content
    A

    Actinium Pharmaceuticals Inc (ATNM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $1.49
    -0.15 (-9.45%)

    Market Cap: $51.56M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Actinium Pharmaceuticals Inc (ATNM) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Actinium Pharmaceuticals are Telomir Pharmaceuticals, Inc. Common Stock (TELO), Mink Therapeutics (INKT) and XBiotech (XBIT). By market cap, Actinium Pharmaceuticals ranks 5th of the 13 companies on this page; Tenax Therapeutics (TENX) is the largest at $73.77M.

    Peer Comparison

    ATNM's revenue growth of -100.0% is below the peer median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Actinium Pharmaceuticals (ATNM)$51.56M4.1x1.3x32.2%N/A-100.0%0.00%
    Telomir Pharmaceuticals, Inc. Common Stock (TELO)$36.15MN/AN/A0.0%N/A0.0%0.00%
    Mink Therapeutics Inc (INKT)$47.95MN/A236.3x0.0%N/A0.0%0.00%
    XBiotech Inc (XBIT)$59.76MN/AN/A0.0%N/A-93.3%0.00%
    Plus Therapeutics Inc (PSTV)$26.64MN/A2.0x-230.2%-827.8%-2.9%0.00%
    Instil Bio Inc. (TIL)$41.23MN/AN/A0.0%-11.9%0.0%0.00%
    MAIA Biotechnology Inc. (MAIA)$61.75MN/AN/A0.0%N/A0.0%0.00%
    Biomea Fusion Inc (BMEA)$42.31MN/AN/A0.0%N/A0.0%0.00%
    Tenax Therapeutics Inc (TENX)$73.77MN/AN/A0.0%N/A0.0%0.00%
    Connect Biopharma Holdings Ltd (CNTB)$42.65MN/A13.6x0.0%N/A5667.0%0.00%
    Gain Therapeutics Inc (GANX)$46.31MN/AN/A0.0%-170.5%-100.0%0.00%
    Fortress Biotech Inc (FBIO)$62.70M0.7x0.8x143.1%57.0%8.7%0.00%
    iBio, Inc. Common Stock (IBIO)$51.55MN/A735.4x0.0%N/A975.0%0.00%
    Peer median$47.13M0.7x13.6x0.0%-91.2%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Actinium Pharmaceuticals, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Telomir Pharmaceuticals, Inc. Common Stock (TELO)
    Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human...
    TELO competitors
    Mink Therapeutics Inc (INKT)
    MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of allogeneic...
    INKT competitors
    XBiotech Inc (XBIT)
    XBiotech Inc., a biopharmaceutical company, discovers, develops and markets True Human monoclonal antibodies for the treatment of various diseases.
    XBIT competitors
    Plus Therapeutics Inc (PSTV)
    Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacturing...
    PSTV competitors
    Instil Bio Inc. (TIL)
    Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer patients.
    TIL competitors
    MAIA Biotechnology Inc. (MAIA)
    MAIA Biotechnology Inc. is an innovative biotechnology company focused on developing cutting-edge cancer therapies that significantly improve patient outcomes...
    MAIA competitors
    Biomea Fusion Inc (BMEA)
    Biomea Fusion, Inc., a biopharmaceutical company, is focused on the discovery, development and commercialization of irreversible small molecules to treat...
    BMEA competitors
    Tenax Therapeutics Inc (TENX)
    Tenax Therapeutics, Inc., a specialty pharmaceutical company, is dedicated to identifying, developing...
    TENX competitors
    Connect Biopharma Holdings Ltd (CNTB)
    Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, is focused on the discovery and development of immune modulators...
    CNTB competitors
    Gain Therapeutics Inc (GANX)
    Gain Therapeutics, Inc., a developing biotechnology company, is dedicated to developing a variety of therapies to treat diseases caused by protein misfolding.
    GANX competitors
    Fortress Biotech Inc (FBIO)
    Fortress Biotech, Inc., a biopharmaceutical company, develops and markets pharmaceutical and biotech products.
    FBIO competitors
    iBio, Inc. Common Stock (IBIO)
    iBio, Inc., a biotech company, provides contract development and manufacturing services to outside partners and customers in the United States.
    IBIO competitors

    Frequently Asked Questions About ATNM

    Who are Actinium Pharmaceuticals' main competitors?

    The companies most similar to Actinium Pharmaceuticals include Telomir Pharmaceuticals, Inc. Common Stock (TELO), Mink Therapeutics (INKT), XBiotech (XBIT), Plus Therapeutics (PSTV) and Instil Bio (TIL), listed from the closest match.

    Who is Actinium Pharmaceuticals' biggest competitor?

    Tenax Therapeutics (TENX) is the largest of the similar companies at $73.77M; Telomir Pharmaceuticals, Inc. Common Stock (TELO) is the closest match by business profile, size, sector and industry.

    How does ATNM stock compare with its competitors?

    ATNM's P/E is 4.1x against a peer median of 0.7x; its P/S is 1.3x against a peer median of 13.6x; its net margin is 32.2% against a peer median of 0.0%.

    Which of Actinium Pharmaceuticals' competitors pays a higher dividend?

    Actinium Pharmaceuticals pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Actinium Pharmaceuticals bigger than its competitors?

    No. Actinium Pharmaceuticals is 5th by market cap among the 13 companies on this page; the largest is Tenax Therapeutics (TENX) at $73.77M.